SAN DIEGO, March 24, 2023 (GLOBE NEWSWIRE) —

The class: Robbins LLP reminds investors that a shareholder has filed a class action lawsuit on behalf of all purchasers of Invivyd, Inc. IVVD f/k/a common stock of Adagio Therapeutics, Inc. between November 29, 2021 and December 14, 2021 for violations of the Securities Exchange Act of 1934. Invivyd, Inc. is a clinical-stage biopharmaceutical company indicted during the Class Period was focused on developing a monoclonal antibody (“mAb”) therapy for the prevention and treatment of COVID-19. The company was founded in June 2020 during some of the worst days of the pandemic to develop medicines to treat and prevent COVID-19 and future coronavirus outbreaks.

What now: Shareholders in a similar situation may be eligible to participate in the class action lawsuit against Invivyd. Shareholders who wish to be lead plaintiffs in the class action must file their filings by April 3, 2023. A Lead Plaintiff is a representative party acting on behalf of other Class Plaintiffs in the conduct of the litigation. You do not have to be present at the case to be eligible for a recovery. Click for more information Here.

All representations are on a contingency fee basis. Shareholders pay no fees or costs.

What is it about in this case: Invivyd, Inc. has misled the public regarding the viability and efficacy of its lead drug candidate ADG20 and the drug’s ability to neutralize the COVID-19 omicron variant

According to the complaint, during the class action, defendants touted their lead product candidate, ADG20, as “a potent, long-acting, and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as a single or combination agent.” At the time of the company’s IPO in August 2021, it claimed that ADG20 had demonstrated “in vitro neutralizing activity against common circulating SARS-CoV-2 variants,” including the alpha, beta, gamma, and delta variants. When the World Health Organization classified Omicron as a VOC in November 2021, Invivyd was…